Find, compare & contact
Insulin Glargine API Manufacturers & Suppliers

Looking for Insulin Glargine API 160337-95-1?

Description:

Here you will find a list of producers, manufacturers and distributors of Insulin Glargine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Insulin Glargine 

Synonyms:

Insulin Glargine (rDNA origin) , Insulin glargine recombinant  

Cas Number:

160337-95-1 

DrugBank number:

DB00047 

Unique Ingredient Identifier:

2ZM8CX04RZ

Insulin Glargine is a type of Insulin

Insulin is a vital pharmaceutical Active Pharmaceutical Ingredient (API) that plays a crucial role in managing diabetes. It is a hormone produced by the pancreas and is responsible for regulating blood sugar levels in the body. Insulin is used extensively in the treatment of diabetes, a chronic condition characterized by insufficient insulin production or impaired insulin action.

As an API, insulin is available in various forms, including human insulin and analog insulin. Human insulin is derived from recombinant DNA technology, where it is synthesized using genetically engineered bacteria or yeast. Analog insulin, on the other hand, is a modified version of human insulin that is designed to mimic the body's natural insulin action more closely.

Insulin APIs are utilized in the production of pharmaceutical formulations such as insulin injections, insulin pens, and insulin pumps. These formulations are essential for individuals with diabetes who require regular insulin administration to maintain proper blood sugar control.

The development and production of insulin APIs require stringent quality control measures to ensure their safety and efficacy. Manufacturing processes must adhere to Good Manufacturing Practices (GMP) to guarantee the purity, potency, and consistency of the API. Additionally, regulatory bodies such as the Food and Drug Administration (FDA) closely monitor the production and distribution of insulin APIs to maintain high standards of quality and patient safety.

In summary, insulin APIs are critical components in the management of diabetes. They are manufactured using advanced biotechnological methods and are utilized in the production of various insulin formulations. Rigorous quality control and regulatory compliance are essential to ensure the effectiveness and safety of insulin APIs for patients with diabetes.

Insulin Glargine (Insulin), classified under Anti-diabetics

Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.

Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.

Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.

In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.

• Nanjing Hanxin Pharmaceutical Technology Co.,Ltd. from China, product country of origin China
• Apino Pharma Co., Ltd. from China, product country of origin China
• Sinoway industrial Co.,Ltd from China, product country of origin China
• Biocon from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.